The 3-year PFS in lymphoma patients mobilized with Plerixafor was 47% (95% CI, 34–60%) vs. 74% (95% CI, 65–81%) in the G-CSF Group (p = 0.003) (Figure 2). The gene discussed is CSF3; the disease is lymphoma.